Payment overview · 2025
General Payments
$540.27
31 reported records · 14 companies
Healthcare provider profile · identity verified
Bryan Ghiloni
Allopathic & Osteopathic Physicians|Family Medicine · NEW ALBANY, OH · NPI 1760429914
Verified facts
What the public records show
CMS Open Payments records show Bryan Ghiloni received $540.27 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.51 | 30.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.26 | 13.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.40 | 10.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.12 | 6.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.45 | 5.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $28.78 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.82 | 5.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.81 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.54 | 3.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.41 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.32 | 3.4% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.71 | 3.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.52 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.62 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $540.27 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.67 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.26 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.17 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.87 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.40 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.45 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.97 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 73 |
| Lisinopril | Lisinopril | 201 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 45 |
| Simvastatin | Simvastatin | 152 | 45 |
| Omeprazole | Omeprazole | 150 | 44 |
| Metformin Hcl | Metformin Hcl | 126 | 34 |
| Carvedilol | Carvedilol | 116 | 34 |
| Gabapentin | Gabapentin | 116 | 32 |
| Losartan Potassium | Losartan Potassium | 107 | 32 |
| Potassium Chloride | Potassium Chloride | 106 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 36 |
| Eliquis | Apixaban | 100 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 30 |
| Valsartan | Valsartan | 89 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 23 |
| Sertraline Hcl | Sertraline Hcl | 83 | 25 |
| Furosemide | Furosemide | 81 | 26 |
| Allopurinol | Allopurinol | 75 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 24 |
| Ozempic | Semaglutide | 67 | 13 |
| Trazodone Hcl | Trazodone Hcl | 67 | 20 |
| Bupropion Xl | Bupropion Hcl | 66 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 63 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 18 |
| Finasteride | Finasteride | 62 | 17 |
| Celecoxib | Celecoxib | 56 | 18 |
| Glimepiride | Glimepiride | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Chlorthalidone | Chlorthalidone | 51 | 14 |
| Glipizide | Glipizide | 49 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Xarelto | Rivaroxaban | 49 | 12 |
| Alendronate Sodium | Alendronate Sodium | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 16 |
| Klor-Con M20 | Potassium Chloride | 42 | 15 |
| Naproxen | Naproxen | 42 | 20 |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Famotidine | Famotidine | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Prednisone | Prednisone | 24 | 16 |
| Atenolol | Atenolol | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $540.27 · 31 records | ABBVIE INC. | AIRSUPRA, Azstarys, CAMZYOS, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, GARDASIL 9, LEQVIO, LINZESS, QULIPTA, Senza, Symbravo, UBRELVY, VRAYLAR, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error